What is the risk of pneumonia associated with adalimumab in a patient with COPD, moderate emphysema, and asthma?
No direct evidence for the risk of pneumonia with adalimumab in COPD, emphysema, and asthma, but general data indicates an increased infection risk. Enhanced monitoring and preventive approaches are advised.
Authors
- Tripdatabase
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-10-26
- DOI
- https://doi.org/10.5281/zenodo.23666166
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00